The regulator joins the EU regulator in refusing to register Leqembi, which gave similar reasons for its position on the drug ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
Medicare patients can be prescribed Leqembi if they’ve been diagnosed with mild cognitive impairment or mild Alzheimer’s disease and their doctor agrees to participating in ongoing data ...
A recent study supported by the National Institutes of Health (NIH) and published in Nature Neuroscience found that Alzheimer ...
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
Tim Sandry has an early form of Alzheimer’s disease, but considers himself fortunate to have started treatment with a promising new drug. “If there is a chance this will slow the progression ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback